NASDAQ:ALDX
Aldeyra Therapeutics Stock News
$3.86
-0.120 (-3.02%)
At Close: Apr 19, 2024
Implied Volatility Surging for Aldeyra (ALDX) Stock Options
09:55am, Thursday, 11'th Nov 2021
Investors need to pay close attention to Aldeyra (ALDX) stock based on the movements in the options market lately.
Aldeyra's Dry Eye Disease Trial Meets Primary Endpoint, But Did Not Reach Statistical Significance
12:44pm, Tuesday, 02'nd Nov 2021
Aldeyra Therapeutics Inc's (NASDAQ: ALDX) reproxalap achieved the primary endpoint of ocular redness in the Phase 2 trial in patients with dry eye disease. But the ocular redness scores in the repro
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2021 Results - Earnings Call Transcript
01:24pm, Thursday, 28'th Oct 2021
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2021 Results - Earnings Call Transcript
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2021 Results - Earnings Call Transcript
06:39pm, Thursday, 05'th Aug 2021
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2021 Results - Earnings Call Transcript
Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer
12:23pm, Wednesday, 21'st Jul 2021
The FDA grants an Orphan Drug designation to Aldeyra's (ALDX) ADX-2191 for the treatment of primary vitreoretinal lymphoma.
Aldeyra Stock Trading Higher On FDA Orphan Drug Tag For Primary Vitreoretinal Lymphoma Candidate
09:19am, Tuesday, 20'th Jul 2021
The FDA has granted Orphan Drug Designation to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) ADX-2191 (methotrexate for intravitreal injection) for primary vitreoretinal lymphoma (PVRL). PVRL is a r
Aldeyra Therapeutics: A New Approach To Ocular Inflammatory Diseases With Impressive Clinical Data
05:55pm, Tuesday, 01'st Jun 2021
Stellar P values in late stage dry eye disease and allergic conjunctivitis studies.
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
08:00am, Thursday, 27'th May 2021
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participa
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q1 2021 Results - Earnings Call Transcript
02:27pm, Thursday, 06'th May 2021
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q1 2021 Results - Earnings Call Transcript
Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
06:31pm, Wednesday, 28'th Apr 2021
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to impro
Why Aldeyra Therapeutics Stock Is Sinking Today
12:53pm, Wednesday, 28'th Apr 2021
The company plans to conduct a public stock offering.
Aldeyra Seeks To Raise $125M Via Equity To Support Reproxalap US Application
06:10am, Wednesday, 28'th Apr 2021
Aldeyra Therapeutics Inc (NASDAQ: ALDX) intends to sell $125 million shares of its common stock in an underwritten public offering. Underwriters will have an option to purchase up to an addition
Why Aldeyra Therapeutics Stock Is Soaring Today
11:06am, Tuesday, 27'th Apr 2021
The company reported great clinical results for its lead pipeline candidate.
ALDX Stock: Over 25% Increase Pre-Market Explanation
07:57am, Tuesday, 27'th Apr 2021
The stock price of Aldeyra Therapeutics Inc (NASDAQ: ALDX) increased by over 25% pre-market. This is why it happened.
Aldeyra Therapeutics Stock Is Trading Higher On Acing Allergic Conjunctivitis Study With Reproxalap
07:40am, Tuesday, 27'th Apr 2021
Aldeyra Therapeutics Inc (NASDAQ: ALDX) has announced positive top-line results from the Phase 3 INVIGORATE trial evaluating 0.25% reproxalap, in patients with allergic conjunctivitis. The 95-su
